H&R GmbH & Co. KGaA

  • WKN: A2E4T7
  • ISIN: DE000A2E4T77
  • Land: Deutschland

Nachricht vom 02.06.2021 | 13:54

H&R GmbH & Co. KGaA wins prize in the Responsible Care competition of VCI Nord

DGAP-News: H&R GmbH & Co. KGaA / Key word(s): Sustainability
02.06.2021 / 13:54
The issuer is solely responsible for the content of this announcement.

H&R GmbH & Co. KGaA wins prize in the Responsible Care competition of VCI Nord

- Pilot plant to prepare the market launch of climate-neutral specialty chemical products is rewarded with 2nd place

Salzbergen, Germany, June 2nd, 2021. H&R GmbH & Co. KGaA earned second place in the Responsible Care competition organized by the Chemical Industry Association North (VCI Nord) with a pilot project for the production of sustainable synthetic products. A power-to-liquids process applied by the company uses the self-produced hydrogen (by electrolysis from green electricity) as well as high-purity biogenic carbon dioxide. The company thereby produces sustainable chemical specialties such as waxes, in addition to the sustainable fuels required to achieve the national climate targets.
The project named "NextGate" by H&R is able to produce around 200 tons of e-fuels and around 150 tons of waxes per year, for applications in cosmetics, pharmaceuticals and the food industry. They are first tested by laboratory analysis and tried out using exemplary utilizations. A market launch in which limited quantities of fuel are sold at gas stations and waxes are supplied to individual wholesale customers is also planned and will demonstrate possible applications. "Based on our already existing hydrogen generating capacity at the Hamburg location and through the use of highly innovative synthesis technology, we will support our claim to leadership in the implementation of climate-friendly product solutions", says H&R's Managing Director Niels H. Hansen. With the project, the company supports the further development of PtX technologies and enables its customers to transform themselves towards climate-neutral products. "In addition, we are gaining important knowledge about further processing steps and future applications for the components produced. At the same time, we are also creating conditions for the use of sustainably produced hydrocarbons on an industrial scale", adds Detlev Wösten, Chief Sustainability Officer of H&R.

Contact information:
H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser
Neuenkirchener Strasse 8, 48499 Salzbergen
Tel.: +49 40 43218-321, Fax: +49 40 43218-390
e-mail: ties.kaiser@hur.com ; www.hur.com

H&R GmbH & Co. KGaA:
H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures crude-oil-based chemical and pharmaceutical specialty products and produces high-precision plastic parts.

Forward-looking statements and forecasts:
This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.

02.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021